Repurposing the anti-asthmatic agent Tranilast into an anti-HIV agent: Tranilast (trade name: Rizaben and others) increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production, via upregulation of its target gene, 26/February/2020, 11.07 pm

Molecular therapy for body weight control, energy homeostasis and TIIDM: TICAM1/TRIF[Toll-like receptor adaptor molecule1/TIR-domain-containing adapter-inducing interferon-beta] decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 24/February/2020, 11.12 pm
February 24, 2020
Repurposing the anti-hypertensive agent into an anti-malarial agent: Nifidipine, a calcium channel blocker, increases Ferroportin expression, decreases intracellular iron accumulation, inhibits cellular damage, prevents hemolysis, and inhibits malaria infection, via upregulation of its target gene, 28/February/2020, 9.39 am
February 28, 2020
Show all

What we say:

Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Repurposing the anti-asthmatic agent Tranilast into an anti-HIV agent: Tranilast (trade name: Rizaben and others) increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production, via upregulation of its target gene, 26/February/2020, 11.07 pm

[easy_payment currency=”USD”]


From Significance of the study to Public health relevance:

Given that: (1) more than 37 million people worldwide are living with HIV/AIDS; (2) there is no effective vaccine available for HIV/AIDS; (3) HIV/AIDS tops the list of incurable diseases in humans; (4) the life-long painful drug treatment is required to treat HIV/AIDS and its associated opportunistic infections; (5) the global economic cost spent for HIV treatment is enormous, there is an urgent need to find: (i) a way to restore CD4 T-cells that were lost in HIV/AIDS; (ii) a cheaper alternative to the existing expensive antiviral drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, HIV-1/AIDS.


Research findings to Therapeutic opportunity:

This study suggests, for the first time, an anti-hypertensive drug-based antiviral therapy against RNA viruses, such as HIV-1.  Tranilast (trade name: Rizaben & others), by increasing the expression of its target gene, it may increase the expression of Heme oxygenase-2 (HO-2) (Figure 1). Thereby, it may: (1) bind and block the myristate moiety of HIV-1 Gag protein; (2) disrupt HIV-1 budding; (3) restrict HIV-1 infectivity, replication, and production; (4) promote clearance of HIV-1 and MLV virions; and (5) strengthen antiviral immunity against RNA viruses (fig.2).

This image has an empty alt attribute; its file name is Tranilast-acts-as-an-antiviral-agent-against-HIV1-virus-through-induction-of-HO2-and-others-770x578.jpg

Figure 1 Mechanistic insights into how Tranilast functions as an anti-HIV agent. Tranilast inhibits HIV-1 budding and production via up-regulation of its target gene HO-2

This image has an empty alt attribute; its file name is Tranilast-acts-as-an-antiviral-agent-against-HIV1-virus-through-induction-of-HO2-and-others.jpg2_-770x578.jpg

Figure 2. The chemical structure of Tranilast (trade name: Rizaben and others). It functions as an anti-HIV agent.through induction of its target gene HO-2

Thus, pharmacological formulations encompassing “Tranilast or its analogs, either alone or in combination with other drugs,” may be used to inhibit HIV-1 production. Together, this study suggests that (1) Tranilast may function as an anti-retroviral agent against HIV infections; and (2) daily intake of Tranilast (low dose) may protect against HIV1 infections.

Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:                          Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Tranilast increase the expression of Heme oxygenase-2 (HO-2)?

Amount: $500#

For payment and purchase details, you may reach us at admin@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Repurposing the anti-asthmatic agent Tranilast into an anti-HIV agent: Tranilast (trade name: Rizaben and others) increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production, via upregulation of its target gene, 26/February/2020, 11.07 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at admin@genomediscovery.org

Comments are closed.